Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...132133134135136137138139140141142...10651066»
  • ||||||||||  Trial completion date, Trial primary completion date:  TT4B: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma (clinicaltrials.gov) -  Aug 9, 2023   
    P3,  N=382, Active, not recruiting, 
    Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024 Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
  • ||||||||||  metyrapone/oxazepam (EMB-001) / Embera NeuroTherap
    Enrollment change, Trial termination:  Study of EMB-001 as a Potential Smoking Cessation Treatment (clinicaltrials.gov) -  Aug 9, 2023   
    P1/2,  N=16, Terminated, 
    Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 N=50 --> 16 | Recruiting --> Terminated; Business decision
  • ||||||||||  dapsone / Generic mfg., prednisolone / Generic mfg., azathioprine / Generic mfg.
    Navigating the Therapeutic Challenges of Chronic Gestational Pemphigoid: A Case Report (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1961;    
    Due to the limited number of reported cases in the literature and considering the similar pathophysiology to bullous pemphigoid, an equivalent approach was adopted, which successfully controlled the dermatosis. Dapsone exerts its anti-inflammatory action by reversibly inhibiting a neutrophil myeloperoxidase that generates a reactive oxygen species from the neutrophil
  • ||||||||||  A rare presentation of lichen planus pemphigoides (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1960;    
    Dapsone exerts its anti-inflammatory action by reversibly inhibiting a neutrophil myeloperoxidase that generates a reactive oxygen species from the neutrophil Case report: A 68-year-old man with a personal history of a hypertension treated with captopril50, presented with a history of
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption - A prospective monocentric exploratory pilot study - (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1884;    
    While remission is achieved in the majority of BP patients by first-line therapy, the guidelines recommend therapy with the anti-CD20 antibody rituximab, high-dose intravenous immunoglobulins, or immunoadsorption (IA) in refractory patients...In addition, all patients received therapy with oral prednisolone (0.5 mg/kg/day, tapered), dapsone (1.5 mg/kg/day) and topical mometasone furoate ointment (lesional application, twice daily)... IA is a relatively safe and effective therapy, even in older age, for patients with severe or refractory BP.
  • ||||||||||  dexamethasone / Generic mfg.
    Retrospective data, Review, Journal:  Effect of glucocorticoids on the development of COVID-19-associated pulmonary aspergillosis: A meta-analysis of 21 studies and 5174 patients. (Pubmed Central) -  Aug 8, 2023   
    In the subgroups, the pooled LOR was higher for high-dose GC (0.90; 95% CI: 0.17, 1.62: p?=?.01) and dexamethasone (0.71; 95% CI: 0.35, 1.07; p?<?.01) but had no significant difference for low-dose GC (0.41; 95% CI: -0.07, 0.89; p?=?.09), and non-dexamethasone GC (0.21; 95% CI: -0.36, 0.79; p?=?.47), treated patients versus controls. GC treatment increases the risk of CAPA development, and this risk is particularly associated with the use of high-dose GC or dexamethasone treatment.
  • ||||||||||  hydrocortisone / Generic mfg.
    Trial primary completion date:  Steroid, Thiamine and Ascorbic Acid for Comatose Out-of-hospital Cardiac Arrest Survivors (clinicaltrials.gov) -  Aug 8, 2023   
    P2,  N=160, Recruiting, 
    GC treatment increases the risk of CAPA development, and this risk is particularly associated with the use of high-dose GC or dexamethasone treatment. Trial primary completion date: Jun 2023 --> Dec 2023
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Trial termination, Combination therapy:  Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study (clinicaltrials.gov) -  Aug 8, 2023   
    P1b,  N=11, Terminated, 
    Trial primary completion date: Jun 2023 --> Dec 2023 Active, not recruiting --> Terminated; Higher than expected occurrence of VTE (venous thromboembolic event)
  • ||||||||||  Journal:  Aseptic meningitis followed by mononeuritis multiplex in a patient with primary Sj (Pubmed Central) -  Aug 7, 2023   
    Comparing groups statistically, the pulsed radiofrequency group had a more delayed, but statistically better long-term improvement compared to the other 2 groups. Although she improved with acyclovir and glyceol, she experienced left forearm pain and sensory disturbance with drop fingers...Because the patient had primary Sj
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Long-term remission of (Pubmed Central) -  Aug 7, 2023   
    Because of the suboptimal response to the initial therapy, cytoreduction therapy consisting of CHOP (combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and PSL) was administered...In 2022, ubiquitylation-initiating E1 enzyme (UBA1) variant analysis using Sanger sequencing of peripheral blood leukocytes detected a previously reported somatic variant (NM_003334.3: c.118-1G>C), confirming the diagnosis of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. The clinical course in the present case suggested the possibility that CHOP could be a potential treatment option for VEXAS syndrome, in the pathophysiology of which the expansion of clones with UBA1 variant seems to play a pivotal role.
  • ||||||||||  dexamethasone / Generic mfg., ciprofloxacin oral / Generic mfg.
    Retrospective data, Journal:  A New Approach for Explaining and Treating Dry Sockets: A Pilot Retrospective Study. (Pubmed Central) -  Aug 7, 2023   
    On the other hand, the other two patients (13.3%) had a negative response to the treatment and were out of reach for follow-up. Conclusion These clinical outcomes, coupled with previous laboratory data, could explain all clinical aspects of dry sockets and provide substantial support for the hypothesis that an infectious mechanism plays the principal role in the pathophysiology of dry sockets.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Adrenal steroid metabolites and bone status in patients with adrenal incidentalomas and hypercortisolism. (Pubmed Central) -  Aug 6, 2023   
    This case suggests that PE may represent a rare type of irAE that should be monitored for during prolonged immuno-oncology therapy. This study demonstrates that unbalanced production of adrenal steroid metabolites, derived from both adrenal tumor and non-tumor tissues, contributes to the pathogenesis of endogenous SIOP in premenopausal women with ACS.
  • ||||||||||  hydrocortisone / Generic mfg.
    Retrospective data, Journal:  Vasopressin and Methylprednisolone and Hemodynamics after In-Hospital Cardiac Arrest - A Post Hoc Analysis of the VAM-IHCA Trial. (Pubmed Central) -  Aug 6, 2023   
    This study demonstrates that unbalanced production of adrenal steroid metabolites, derived from both adrenal tumor and non-tumor tissues, contributes to the pathogenesis of endogenous SIOP in premenopausal women with ACS. Treatment with vasopressin and methylprednisolone during cardiac arrestcaused no difference in mean arterial blood pressure, vasopressor use, or arterial blood gases within the first 24 hours after ROSC when compared to placebo.
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    Reimbursement, Retrospective data, US reimbursement, Journal, HEOR, Medicare, Real-world evidence, Real-world:  Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States. (Pubmed Central) -  Aug 4, 2023   
    There is limited literature regarding real-world treatment patterns of patients with COPD, particularly since the introduction of once-daily single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol in 2017...Although the percentage of patients receiving a controller medication increased following a first exacerbation, it remained below 50%. Of patients receiving controller medications pre-exacerbation, only a small proportion escalated to triple therapy post-exacerbation.